Member Info for LordSnooty

Honk Kong: a special place just offshore from mainland China, renowned for its loud nasal evacuations.

A young couple left the church and arrived at the hotel where they were spending the first night of their honeymoon. They opened the champagne and began undressing. When the bridegroom removed his socks, his new wife asked, "What's wrong with your feet? Your toes look all mangled and weird. "I had tolio as a child," he answered. You mean polio?" she asked. No, tolio. The disease only affected my toes." When the groom took off his pants, his bride once again asked, "What's wrong with your knees? They're all lumpy and deformed!" "As a child, I also had kneasles," he explained. You mean measles?" She asked. "No, kneasles. It was a strange illness that only affected my knees." The new bride had to be satisfied with this answer. As the undressing continued, her husband at last removed his underwear. "Don't tell me," she said. "Let me guess... ..... "Smallcox?"

that Changi 69 has again stunned the thread into silence with yet another spectacularly tasteless joke....

He said these locations were chosen because it is cost effective to run big market drug trials there, and the structure of the trials reflects the Food & Drug Administration (FDA) format so it's an easy transition into the US or Europe markets after phase 2 trials. Importantly, however, in Russia, where the drug is currently in trials, there is a chance to see revenues from ErepoXen sooner. In Russia, Xenetic hopes to see a commercial launch of the drug in the second half of next year and it will be receiving a 10% royalty on its sales in Russia. Another candidate the firm is excited about, and which will be added to its portfolio for the western markets, is OncoHist for acute myeloid leukaemia. Maguire told a conference call last month that he was "particularly" excited about this drug, which he said had "multi-billion dollar" potential. OnCoHist binds itself to leukaemia cells and leaves healthy cells alone, so there are no serious side effects. Maguire said a world-leading specialist described it as being the first novel mode of action for the disease he had seen in 20 years. The firm continues to test the efficacy of this drug and crucial phase 2 data is expected this summer. Part of the plans to expand into western markets is the move this September of staff to lab and development operations to Boston, USA - the world's leading centre for orphan drug development. Xenetic has also just announced it will look for a merger with an SEC reporting, unlisted US company, a move that will enable it get a quote on a major US stock market within a reasonable period. It wants to agree a deal in 2013, a move that will also see it de-list from AIM. Maguire said the long term benefits of being a US-centric organisation will become apparent as US markets give "significantly" greater value to firms like Xenetic with its broad proprietary drug pipeline.

Xenetic Biosciences expects higher rating from US switch By Giles Gwinnett July 17 2013, 1:35pm Xenetic Biosciences (LON:XEN) is finally embarking on the process of "serious value" growth, according to its chief executive. This week Xenetic announced it is searching for a suitable candidate to reverse into to get a US listing, while the company’s own development programmes for potential blockbuster drugs for western markets also starts soon. Chief executive Scott Maguire recently colourfully compared this process as being like a "battleship leaving the dock". He's referring to the first western clinical trial of ErepoXen for treating chronic anaemia, which is starting in Australia at the end of this month or next - one of several drugs in the firm's portfolio and a candidate that the firm wholly controls. Maguire explains that previously Xenetic has been purely research-based, relying on out-licensing partnerships and collaborations with groups in India and Russia. But, following a fundraising last year, the company has now begun the process of evolving into a drug developer, able to test and commercialise its own products. Maguire is so excited about this transition because, not only does if offer potentially large rewards for shareholders, but also because the firm's portfolio itself is highly promising. Xenetic specialises in developing orphan drugs for rare diseases, which have multi-billion dollar potential. Orphan drugs are fast-tracked to the market because they typically address diseases and conditions for which there are few, if any, medications. Now, following the firm's undeniable progress thus far, what is needed, is delivering on plans and, of course, securing financing, reckons Maguire. "As I see it, as management, the science is working and it's going to come down to a function of execution and money to deliver on the promise, because it's clear that these products we have in development have blockbuster potential and those are not my words, those are words from the investment and strategic community," he said. And Maguire highlighted all three of its technological platforms - PolyXen, ImuXen, OncoHist - have products in at least phase 2 clinical trials. Currently, its main focus is ErepoXen - the firm's most advanced product and likely to be the key share driver. Ironically, perhaps, this drug is one that does not fit into the firm's orphan strategy, in that it is a big, mass-market candidate. Maguire says the plan is to complete a dose finding study for western markets in December this year before striking a deal. "The goal of ErepoXen is to out-license as soon as allowable and there is already some interest in this product," he adds. "This is a big market drug, very expensive clinical trials, so we are going to be seeking a partner to out-license this as soon as we have data coming out of Australia/New Zealand.

that's they way to do it!

clearly you are not the brightest bulb at the electricians' so I will spell it out for you: my recent post was in response to Juggler's two comments implying the bright prospects in the junior diamond mining industry. You are quite right that the closure of the pilot plant will stem somewhat - though not plug - the haemorrhaging of money from FDI. This despite the ongoing C&M costs at BK11. However, the problems remain the same. Do I need to reiterate yet again exactly what they are?

is that, according to the RNS of 16 July the pilot plant at Liqhobong will be shut down before the end of this year , leaving FDI with no source of income for at least eighteen months. In addition, "The market conditions in the mining industry are currently very challenging and the diamond industry is no exception. These conditions are particularly difficult for the junior mining sector". As for BK11, the "mine remains under care and maintenance. The Board is considering various strategic alternatives for this operation, but it recognises that extracting fair value from the asset in the current investor climate could be challenging".

would like to apologise to any newcomers who have strayed onto this thread by happenstance. Mad Dog Leeson has slipped his leash again and, as can be seen below, has resumed posting pornography.

172 is simply the number of dud jokes that Leeson has told on this thread. Even the market makers are becoming irritated.

I think news from September to the end of the year will have something for everyone.

I think US news before Onco.

another meaty buy at above ask, another opprobrious joke from the jailbird formerly known as Changi 8366451. Now long now, acolytes - mark Snooty's words.

are taking the opportunity to top up today, at bargain basement prices. Would that Her Ladyship had not sewn the family ingots into her corsets, against the depredations of Snooty..

levity is amusing, no doubt, to those with simple tastes. However, let us apply ourselves to the task at hand. As followers of Snooty's knowledgeable and erudite posts will no doubt be aware, XEN languishes in the doldrums of AIM. Do not expect this situation to continue for much longer; time is fast running out to convert those last few baubles of costume jewellery inherited from Great Aunt Hilda into the hard currency of a few XEN shares. Clutch the certificates in your gnarled, sweaty hands for a few months and reap the rewards, I say!

Just when one looked forward to a nice, peaceful Bank Holiday....

Like those two 200k trades could be a rollover.

fellow people of the XEN: we are stuck with Leeson and his appalling jokes for the duration.

Kindly refer to my post of last Friday 08:45am. You call this a risky investment yet, as Mr M has explained tirelessly, we are triply de-risked. XEN is not your run-of-the-mill wide boy junior pharma. We are the gold standard of the sector and will shortly spread our wings and migrate to sunnier shores. So yes, time is short and an 8% spread should not, in my overly modest opinion, be an impediment to buying a lavish chunk of this most excellent of investments.

this jailbird Leeson is more tenacious than I had thought. Extra measures will have to be deployed to uproot his appalling jokes once and for all....